Predict Breast (
Predict Breast is an innovative, web-based prognosis and decision support tool that helps patients and clinicians assess the effectiveness of various treatment options after surgery for early invasive breast cancer. Developed and continuously improved with extensive clinical data from the UK and internationally validated, Predict provides accurate, individualized predictions of survival rate and the benefit of different therapeutic approaches[2][3][4][8].
The main mission of Predict Breast is to promote personalized cancer therapy through evidence-based prognostic models, thereby improving the quality of life and treatment outcomes of breast cancer patients worldwide. The company places great emphasis on clinical accuracy and user-friendliness and is officially recognized by the American Joint Committee on Cancer (AJCC), which underscores the scientific credibility of the platform[2][3][4].
In addition to clinical application, the company is also committed to innovation and progress in cancer research. BREAST-PREDICT, an Ireland-based partner project, uses state-of-the-art biological and computational methods to analyze individual tumor characteristics and develop new therapeutic approaches. This is intended to better match patients to specific drugs and explore new combinations of therapies. The project involves a nationwide collaboration of leading academic centers and focuses on improving the prediction accuracy for treatment success and disease progression[7][9].
Sustainability and ethical responsibility are reflected in the use of existing, extensive data sets to avoid unnecessary invasive procedures and to promote evidence-based, resource-efficient medicine. The digital provision of the tool also minimizes physical resources and facilitates worldwide access without geographical barriers.
Overall, Predict Breast combines state-of-the-art data analysis, clinical excellence and a collaborative research platform to make breast cancer treatment precise, transparent and patient-centered. This makes the company a significant player in the field of personalized oncology and supports major advances in decision-making in everyday clinical practice.
